You are viewing the site in preview mode
Skip to main content
|
Country
|
All PGD Patients(%)
|
Patients with nephrotic syndrome
|
Biopsy indication (%)
|
|---|
|
1st
|
2nd
|
3rd
|
1st
|
2nd
|
3rd
|
Nephrotic syndrome
|
AUA
|
|---|
|
Turkey (TSN-GOLD 2014) [5]
|
MN (28.8%)
|
FSGS (19.3%)
|
IgAN (17.2%)
|
MN (43.2%)
|
FSGS (19.7%)
|
MCD (10.3%)
|
57.8
|
10.8
|
|
Turkey (TSN-GOLD 2019)a
|
IgAN (25.7%)
|
MN (25.6%)
|
FSGS (21.9%)
|
MN (39.8%)
|
FSGS (25.2%)
|
MCD (11.0%)
|
52
|
18
|
|
France [23]b
|
IgAN (29.7%)
|
MN (19.0%)
|
CGN (16.8%)
|
–
|
–
|
–
| | |
|
Italy [24]
|
IgAN (43.5%)
|
MN (23.4%)
|
FSGS (13.1%)
|
MN (44.1%)
|
FSGS (16.9%)
|
MCD (16.7%)
|
45
|
51
|
|
Spain [25]c
|
–
|
–
|
–
|
MN
|
MCD
|
FSGS
|
35
|
25
|
|
England [26]
|
IgAN (38.8%)
|
MN (29.4%)
|
MCD (9.8%)
|
–
|
–
|
–
| | |
|
Czech Republic [27]c
|
IgAN (34.5%)
|
MCD (12.5%)
|
Mes.PGN(%11.3)
|
IgAN**
|
MN
|
FSGS
|
42
|
37
|
|
Lithuania [28]
|
IgAN(34%)
|
FSGS (13.2%)
|
MPGN (12.5%)
|
–
|
–
|
–
| | |
|
Japan [29]
|
IgAN (~ 50%)
|
–
|
–
|
MCD (40%)
|
MN (35.6%)
|
FSGS (13%)
|
16.5
|
48d
|
|
South Korea [30]
|
IgAN (38.2%)
|
MCD
|
MN
|
MCD (38.5%)
|
MN (25.7%)
|
IgAN (11.1%)
| | |
|
China [31]
|
IgAN (45.2%)
|
Mes. PGD (25.6%)
|
MN (9.9%)
|
–
|
–
|
–
| | |
|
Brazil £ [32]
|
FSGS (29.7%)
|
MN (20.7%)
|
IgAN (17.8%)
|
–
|
–
|
–
|
41.5
|
27.2
|
|
U.S.A. [18, 33]e
|
FSGS
|
IgAN
|
MN
|
FSGS
|
MN
|
MCD
| | |
|
Taiwan [34]
|
IgAN (26%)
|
FSGS (21.6%)
|
MN (20.6%)
|
MN (28.8%)
|
MCD (28.2%)
|
FSGS (24.8%)
| | |
|
Colombia [11]f
|
IgAN (22.6%)
|
FSGS (20.1%)
|
MN (14.9%)
| | | | | |
|
Poland [12]
|
IgAN (51.2%)
|
MPGN (19.3)
|
MN (11.2%)
|
MN
|
FSGS
|
IgAN
| | |
- Abbreviations: AUA Asymptomatic urinary abnormalities, CGN crescentic glomerulonephritis, FSGS Focal segmental glomerulosclerosis, IgAN IgA nephropathy, MCD minimal change disease, Mes.PGN Mesangioproliferative glomerulonephritis (non-IgA), MN membranous nephropathy, MPGN membranoproliferative glomerulonephritis, PGD primary glomerular disease, TSN-GOLD Turkish Society of Nephrology Glomerular Diseases
- a Current study; b cumulative data of different age and periods, c including pediatrics cases, d This percentage was presented as the percentage of nephritic syndrome, but asymptomatic urinary abnormalities seem to be involved also. e These results are the combination of two different studies [9, 10], f including secondary cases
